Such data are critical to determining the clinical utility of adipokine receptor expression profiles as biomarkers of breast cancer risk and prognosis and might contribute to the development of novel interventions and therapeutics targeting high breast tumor expression of these markers, particularly of LEPR, as a means of improving outcomes. The gene discussed is LEPR; the disease is breast cancer.